Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc. (DMAC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 (rhKLK1) protein. The company focuses on two primary indications: preeclampsia (PE) and fetal growth restriction (FGR), and acute ischemic stroke (AIS). DM199 has received FDA Fast Track designation for AIS. The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(32,766) | $(24,444) |
| Operating Expenses | $34,397 | $26,681 |
| Research & Development (R&D) | $24,614 | $19,057 |
| General & Administrative (G&A) | $9,783 | $7,624 |
| Cash, Cash Equivalents & Marketable Securities | $59,890 | $44,147 |
| Working Capital | $55,497 | $39,220 |
| Accumulated Deficit | $(172,768) | $(140,002) |
Liquidity: As of December 31, 2025, the company held approximately $59.9 million in cash and marketable securities. Management expects these resources to fund operations for at least the next 12 months. The company raised approximately $43.9 million in net proceeds during 2025 through a private placement and an at-the-market (ATM) offering.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $8.3 million (34%) from 2024 to 2025, driven primarily by higher R&D and G&A expenses.
- R&D Expense Growth: R&D expenses rose by $5.5 million (29%) due to the continuation and global expansion of the ReMEDy2 Phase 2/3 trial for AIS, the initiation of the Phase 2 PE trial, and increased share-based compensation.
- G&A Expense Growth: G&A expenses increased by $2.2 million (29%) due to higher personnel costs, share-based compensation, investor relations expenses, and patent prosecution costs.
- Capital Position: Cash and marketable securities increased by $15.7 million, reflecting the successful equity financings in 2025 which offset the increased operating cash burn.
Guidance, Outlook, and Risks
Clinical Program Updates
- Preeclampsia (PE): Interim results from Part 1a of the Phase 2 investigator-sponsored trial (released July 2025) showed DM199 was safe, well-tolerated, and demonstrated rapid, statistically significant blood pressure reductions with no placental transfer. The company is preparing for Part 1b and a new Phase 2 study in North America/UK. However, the FDA requested an additional non-clinical embryo-fetal development study in a rabbit model; preliminary results suggest an antibody response in rabbits, potentially delaying the U.S. IND filing while alternative models are evaluated.
- Acute Ischemic Stroke (AIS): The ReMEDy2 Phase 2/3 trial is ongoing but experiencing slower-than-expected site activations and enrollment. Causes include staffing shortages, protocol logistics, and competition for subjects. The company has expanded its internal clinical team to mitigate these delays. The trial targets 300 to 728 patients with an interim analysis planned after 200 participants.
Outlook and Guidance
The company does not expect to generate product revenue for at least two to three years. Operating losses are expected to increase moderately in the near term as clinical programs expand. Management anticipates needing substantial additional capital to complete development and regulatory activities.
Key Risks and Contingencies
- Regulatory Delays: Potential delays in the U.S. PE program due to the FDA's request for additional non-clinical studies and the challenges in finding an appropriate animal model.
- Enrollment Risks: Continued slow enrollment in the ReMEDy2 trial could delay the interim analysis and increase costs.
- Capital Requirements: The company has no debt but relies on equity financing. Failure to secure additional funding could force cost reductions, program delays, or asset divestiture.
- PFIC Status: The company was classified as a Passive Foreign Investment Company (PFIC) for 2025, 2024, and 2023, which may have adverse tax consequences for U.S. shareholders.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $59.9 million cash balance against the projected burn rate, considering the potential for increased costs due to trial delays.
- PE Regulatory Path: Monitor the resolution of the FDA's request for the rabbit embryo-fetal development study and the timeline for filing the U.S. IND for the PE program.
- ReMEDy2 Enrollment: Track the rate of site activation and patient enrollment in the ReMEDy2 trial to assess the likelihood of meeting the interim analysis timeline (currently estimated for the second half of 2026).
- Capital Markets: Assess the company's ability to raise additional capital given the current market conditions for clinical-stage biotechs and the dilution impact of future equity issuances.
- Intellectual Property: Review the patent portfolio expiration dates (ranging from 2033 to 2045) and the terms of the license agreement with Catalent Pharma Solutions regarding milestone and royalty obligations.